natgillin/translations-raw huggingface dataset:
CYP3A4-hæmmere (som f.eks. clarithromycin, telithromycin og nefazodon) forventes at have en effekt, der ligger imellem ritonavir og CYP3A4-hæmmere (som f.eks. saquinavir/erythromycin), formodet en 7-gange øgning i eksponering.
CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone) are expected to have an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or erythromycin), a seven-fold increase in exposure is assumed.
CYP3A4-hæmmere og CYP2C9-hæmmere
CYP3A4 inhibitors and CYP2C9 inhibitors
CYP3A4-hæmmere påvirker dog ofte også P-gp.
However, CYP3A4 inhibitors often also affect P- gp.
CYP3A4-hæmmere som potentielt kan øge tacrolimus’ blodkoncentrationer
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels
CYP3A4-hæmmere, bør det overvejes at øge Votubia-dosis fra 10 mg/dag til 20 mg/dag med stigninger på 5 mg eller mindre på dag 4 og 8 efter opstart af behandling med induktor.
If patients require co-administration of a potent CYP3A4 inducer, a Votubia dose increase from 10 mg daily up to 20 mg daily should be considered using 5 mg increments or less applied on Day 4 and 8 following start of the inducer.
CYP3A4-hæmmere, der potentielt medfører øgede blodkoncentrationer af tacrolimus
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels
CYP3A4-hæmmere, og de kan forventes at
CYP3A4 inhibitors and would be
CYP3A4-hæmmere, som ketoconazol, itraconazol eller fluconazol (bruges til behandling af svampeinfektioner)
CYP3A4 inhibitors such as ketoconazole, itraconazole, or fluconazole (used for treatment of fungal infections),
CYP3A4-hæmmere:
CYP3A4 inhibitors:
CYP3A4-hæmmere: En interaktionsundersøgelse med buprenorphin og ketoconazol (en potent CYP3A4-hæmmer) resulterede i øget Cmax og AUC (areal under kurven) af buprenorphin (henholdsvist cirka 50 % og 70 %) og i mindre grad af norbuprenorphin.
CYP3A4 inhibitors: an interaction study of buprenorphine with ketoconazole (a potent inhibitor of CYP3A4) resulted in increased Cmax and AUC (area under the curve) of buprenorphine (approximately 50 % and 70 % respectively) and, to a lesser extent, of norbuprenorphine.
CYP3A4-hæmning
CYP3A4 inhibition
CYP3A4-hæmning skyldes
CYP3A4 inhibition likely due to
CYP3A4-hæmning skyldes
CYP3A4 inhibition likely due to lopinavir/ritonavir.
CYP3A4-hæmning.
CYP3A4 inhibition by atazanavir
CYP3A4-hæmning.
CYP3A4 inhibition.
CYP3A4-hæmning: Baseret på kliniske data synes kendte og ukendte uspecifikke CYP3A4- hæmmere ikke at have klinisk relevant virkning på zonisamids farmakokinetiske eksponeringsparametre.
CYP3A4 inhibition: Based upon clinical data, known specific and non-specific CYP3A4 inhibitors appear to have no clinically relevant effect on zonisamide pharmacokinetic exposure parameters.
CYP3A4-inducere som potentielt kan nedsætte tacrolimus’ blodkoncentrationer
CYP3A4 inducers potentially leading to decreased tacrolimus blood levels
CYP3A4-inducere, der potentielt kan forårsage nedsatte blodkoncentrationer af tacrolimus
CYP3A4 inducers potentially leading to decreased tacrolimus blood levels
CYP3A4-inducerende stoffer (antikrampemidler [f.eks. carbamazepin, phenobarbital, phenytoin, fosphenytoin, primidon], rifampicin, perikon)
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum)
CYP3A4-inducerende stoffer (antikrampemidler [fx carbamazepin, phenobarbital, phenytoin, fosphenytoin, primidon], rifampicin, perikon)
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum [St. John’s wort])
CYP3A4-inducerende stoffer (antikrampemidler [fx carbamazepin, phenobarbital, phenytoin, fosphenytoin, primidon], rifampicin, perikum)
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin,
CYP3A4-inducerende stoffer: Samtidig brug af CYP3A4-inducerende stoffer med buprenorphin kan nedsætte plasma-buprenorphin, hvilket potentielt kan resultere i sub-optimal behandling af opioidafhængighed.
CYP3A4 inducers: Concomitant use of CYP3A4 inducers with buprenorphine may decrease buprenorphine plasma concentrations, potentially resulting in sub-optimal treatment of opioid dependence with buprenorphine.
CYP3A4-induktion)
adequately evaluated.
CYP3A4-induktorer
Inducers of CYP3A4
CYP3A4-induktorer (såsom, men ikke begrænset til avasimib, carbamazepin, phenobarbital, phenytoin, rifabutin, rifampicin, perikon (Hypericum perforatum))
CYP3A4 inducers (such as, but not limited to, avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin (rifampicin), St.John’s wort (Hypericum perforatum))
CYP3A4-induktorer kan øge metaboliseringen af sirolimus og nedsætte sirolimusniveauet i blodet (f.eks. perikon (Hyperikum perforatum) antiepileptika: carbamazepin, phenobarbital, phenytoin).
Inducers of CYP3A4 may increase the metabolism of sirolimus and decrease sirolimus blood levels (e.g., St. John's Wort (Hypericum perforatum), anticonvulsants: carbamazepine, phenobarbital, phenytoin).
CYP3A4-induktorer kan øge metaboliseringen af sirolimus og nedsætte sirolimusniveauet i blodet (f.eks. perikon (Hyperikum perforatum), antiepileptika: carbamazepin, phenobarbital, phenytoin).
Inducers of CYP3A4 may increase the metabolism of sirolimus and decrease sirolimus blood levels (e.g., St. John's Wort (Hypericum perforatum), anticonvulsants: carbamazepine, phenobarbital, phenytoin).
CYP3A4-induktorer og -hæmmere
CYP3A4 inducers and inhibitors
CYP3A4-induktorer ser ud til at have en betydelig indvirkning på farmakokinetikken af oralt administreret sildenafil hos patienter med pulmonal arteriel hypertension, hvilket er bekræftet i et in- vivo interaktionsstudie med CYP3A4-induktoren bosentan.
CYP3A4 inducers seemed to have a substantial impact on the oral pharmacokinetics of sildenafil in pulmonary arterial hypertension patients, which was confirmed in the in-vivo interaction study with CYP3A4 inducer bosentan.
CYP3A4-induktorer såsom carbamazepin, dexamethason, phenobarbital, phenytoin og rifampicin kan reducere Qterns glucosesænkende effekt.
Using CYP3A4 inducers like carbamazepine, dexamethasone, phenobarbital, phenytoin, and rifampicin may reduce the glycaemic lowering effect of Qtern.
CYP3A4-induktorer: CYP3A4-induktorer (fx rifampicin, barbiturater, phenytoin, Hypericum perforatum [perikon]) kan nedsætte eksponeringen over for ivabradin og aktiviteten af ivabradin.
CYP3A4 inducers: CYP3A4 inducers (e.g. rifampicin, barbiturates, phenytoin, Hypericum perforatum [St John’s Wort]) may decrease ivabradine exposure and activity.
CYP3A4-inhibitorer
CYP3A4 inhibitors
CYP3A4-medieret metabolisme kan være en mindre væsentlig metaboliseringsvej.
CYP3A4 mediated metabolism may be a minor pathway.
CYP3A4-metaboliserede HMG-CoA-reduktasehæmmere (f.eks. simvastatin, atorvastatin og lovastatin) på grund af en øget risiko for skeletmuskulaturtoksicitet, herunder rabdomyolyse.
CYP3A4 metabolised HMG-CoA reductase inhibitors (eg simvastatin, atorvastatin and lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis
CYP3A4-substrater, der vides at have et snævert terapeutisk indeks (f.eks. astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil eller sekalealkaloider (ergotamin, dihydroergotamin)) bør derfor administreres med forsigtighed hos patienter, der får lenvatinib.
CYP3A4 substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine)) should therefore be administered with caution in patients receiving lenvatinib.
CYP3A4-substrater, der vides at have et snævert terapeutisk indeks (f.eks. astemizol, terfenadin, cisaprid, pimozid, quinidin, bepridil eller ergot-alkaloider (ergotamin, dihydroergotamin)) bør derfor administreres med forsigtighed hos patienter, der får lenvatinib.
CYP3A4 substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine)) should therefore be administered with caution in patients receiving lenvatinib.
CYP3A4-substrater, og samtidig indgift med
CYP3A4 substrates and co-administration with
CYP3A4.
administration.
CYP3A4.
by rifampicin.
CYP3A4.
Cmax
CYP3A4.
cobicistat
CYP3A4.
inhibition by
CYP3A4.
Mechanism: CYP3A4
CYP3A4.
ritonavir.
CYP3A4.)
inhibition)
CYP3A4/5-hæmmere har vist sig at have en signifikant virkning på guanfacins farmakokinetik ved samtidig administration.
CYP3A4/5 inhibitors have been shown to have a significant effect on the pharmacokinetics of guanfacine when co-administered.
CYP3A4/5-substrater, inkl. immunsupprimerende midler
CYP3A4/5 substrates including immunosuppressants
CYP3A4/P-
n and
Cypern
Κύπρος
Cypern/Κύπρος
Cyprus/ Κύπρος
Cyramza 10 mg/kg eller placebo og docetaxel 75 mg/m2 blev hver især administreret ved intravenøs infusion på dag 1 i en serie på 21 dage.
Cyramza at 10 mg/kg or placebo and docetaxel at 75 mg/m2 were each administered by intravenous infusion on day 1 of a 21-day cycle.
Cyramza 10 mg/ml koncentrat til infusionsvæske, opløsning
Cyramza 10 mg/ml concentrate for solution for infusion
Cyramza 10 mg/ml sterilt koncentrat ramucirumab
Cyramza 10 mg/ml sterile concentrate ramucirumab
Cyramza anvendes i kombination med docetaxel hos patienter, hvis sygdom er blevet værre trods behandling med lægemidler, der indeholder platin.
Cyramza is used in combination with docetaxel in patients whose disease has worsened despite treatment with medicines containing platinum.
Cyramza anvendes i kombination med et andet lægemiddel, paclitaxel, eller alene hvis kombinationen med paclitaxel ikke er hensigtsmæssig, hos patienter hvis sygdom er blevet værre trods behandling med lægemidler, der indeholder platin og fluorpyrimidiner metastatisk kolorektal cancer (kræft i tyktarmen, der har bredt sig til andre dele af kroppen).
Cyramza is used in combination with another medicine, paclitaxel, or on its own if the combination with paclitaxel is not appropriate, in patients whose disease has worsened despite treatment with medicines containing platinum or fluoropyrimidines; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Cyramza anvendes med "FOLFIRI"-kemoterapi (en kombination af fluoruracil, folinsyre og irinotecan) hos patienter, hvis sygdom er blevet værre, trods behandling med bevacizumab, oxaliplatin og et fluoropyrimidin ikke-småcellet lungekræft, der er fremskreden eller har bredt sig til andre dele af kroppen.
Cyramza is used with ‘FOLFIRI’ chemotherapy (a combination of fluorouracil, folinic acid and irinotecan) in patients whose disease has worsened despite treatment with bevacizumab, oxaliplatin and a fluoropyrimidine; non-small cell lung cancer that is advanced or has spread to other parts of the body.
Cyramza fås i pakninger med:
Cyramza is available in packs of:
Cyramza fås kun på recept, og behandlingen bør iværksættes og overvåges af en læge med erfaring i kræftbehandling.
It can only be obtained with a prescription and treatment should be started and supervised by a specialist who has experience in the treatment of cancer.
Cyramza fås som et koncentrat, der efter opløsning indgives med drop (ved infusion) i en vene.
Cyramza is available as a concentrate to be made up into a solution for infusion (drip) into a vein.
Cyramza har vist sig at forlænge overlevelsen af patienter, som har fremskreden kræft i mavesækken eller i overgangen mellem mavesækken og spiserøret, metastatisk kolorektal cancer og fremskreden eller metastatisk ikke-småcellet lungekræft, og hos hvem sygdommen er blevet værre trods behandling med andre lægemidler i fire hovedundersøgelser.
Cyramza has been shown to increase survival of patients with advanced gastric or gastro-oesophageal junction cancer, metastatic colorectal cancer and advanced or metastatic non-small cell lung cancer whose disease has worsened despite treatment with other medicines in 4 main studies.
Cyramza kan forårsage blodpropper i arterierne.
Cyramza can cause blood clots in your arteries.
Cyramza påvirker så vidt vides ikke evnen til at føre motorkøretøj og betjene maskiner.
Cyramza has no known influence on the ability to drive and use machines.
Cyramza som enkeltstof
Cyramza as a single agent
Cyramza viste sig også at forlænge overlevelsen hos patienter med kolorektal og ikke-småcellet lungekræft.
Cyramza was also shown to prolong survival of patients with colorectal and non-small cell lung cancer.
Cystadane
EU/1/06/379/001
Cystadane anvendes til behandling af homocystinuri.
Cystadane is used to treat homocystinuria.
Cystadane anvendes til patienter med alle tre former for homocystinuri, der skyldes mangel på de stoffer, der nedbryder methionin ("cystathionin-beta-syntase" eller "5,10-methylentetrahydrofolatreduktase") eller defekter i kobalamin-kofaktorstofskiftet.
Cystadane is used in patients with all three known types of homocystinuria, caused by a lack of the substances required for the breakdown of methionine (‘cystathionine beta-synthase’ [CBS] or ‘5,10- methylene-tetrahydrofolate reductase’[MTHFR]), or by defects in ‘cobalamin cofactor metabolism’ (cbl).
Cystadane bør ikke anvendes til patienter, der kan være overfølsomme (allergiske) over for betain.
Cystadane should not be used by patients who may be hypersensitive (allergic) to betaine.
Cystadane er et hvidt krystallinsk frit strømmende pulver.
Cystadane is a white crystalline free flowing powder.
Cystadane er et oralt pulver, der indeholder det aktive stof betain, vandfrit.
Cystadane is a powder for oral use that contains the active substance betaine anhydrous.
Cystadane påvirker ikke eller i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Cystadane has no or negligible influence on the ability to drive and use machines.
Cystadane, 1 g oralt pulver Betain, vandfrit
Cystadane 1 g oral powder Betaine anhydrous
Cystadanes udseende og pakningsstørrelse
What Cystadane looks like and contents of the pack
Cystadene 1 g oralt pulver.
Cystadane 1 g oral powder
Cystagon 150 mg: hvide, ugennemsigtige hårde kapsler med CYSTAGON 150 på selve glasset og MYLAN på låget.
Cystagon 150 mg: white, opaque hard capsules with CYSTAGON 150 on the body and MYLAN on the cap.
Cystagon 50 mg: hvide, ugennemsigtige hårde kapsler med CYSTA 50 på selve glasset og MYLAN på låget.
Cystagon 50 mg: white, opaque hard capsules with CYSTA 50 on the body and MYLAN on the cap.
CYSTAGON anvendes til behandling af diagnosticeret nephropatisk cystinosis.
CYSTAGON is indicated for the treatment of proven nephropathic cystinosis.
CYSTAGON indeholder:
What CYSTAGON contains
CYSTAGON kan forårsage sløvhed.
CYSTAGON may cause drowsiness.
CYSTAGON påvirker i mindre eller moderat grad evnen til at føre motorkøretøj eller betjene maskiner.
CYSTAGON has minor or moderate influence on the ability to drive and use machines
CYSTAGON påvirker i mindre eller moderat grad evnen til at føre motorkøretøj eller betjene maskiner.
CYSTAGON has minor or moderate influence on the ability to drive ans use machines
CYSTAGON udseende og pakningsstørrelse
What CYSTAGON looks like and contents of the pack
CYSTAGONs virkning, og hvad Du/de skal bruge det til
You may need to read it again.
Cyste i brystet, opsvulmet clitoris, forstørret clitoris, genitalkløe, brænden i vagina
Breast cyst, clitoral engorgement, enlarged clitoris, genital pruritus, vaginal burning sensation
Cyste i nyren
Cyst in the kidney
Cysteamin er undertiden blevet sat i forbindelse med reversibel leukopeni og undersøgelser af abnorm leverfunktion.
Cysteamine has occasionally been associated with reversible leukopenia and abnormal liver function studies.
Cysteamin påvirker i mindre eller moderat grad evnen til at føre motorkøretøj eller betjene maskiner.
Cysteamine has minor or moderate influence on the ability to drive and use machines.
Cysteamin reducerer cystin akkumuleringen i visse celler (f.eks. leukocytter, muskelceller og leverceller) hos patienter med nephropatisk cystinosis, og hvor behandlingen iværksættes tidligt forsinker det udviklingen af nyresvigt.
Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Cysteaminbitartrat (CYSTAGON) er bioekvivalent med cysteaminhydroklorid og fosfocysteamin.
Cysteamine bitartrate (CYSTAGON) is bioequivalent to cysteamine hydrochloride and phosphocysteamine.
Cysteaminbitartrat med hurtig udløsning
Immediate-release cysteamine bitartrate
Cystedannelse i bugspytkirtlen
Cyst formation in your pancreas
Cystedannelse på bugspytkirtlen
Cyst formation in your pancreas
Cyster i ledkapslerne (synoviale cyster)
Cysts in the lining of joints (synovial cysts)
Cyster i testiklerne
Testicular cyst
Cyster i testiklerne.
Testicular cyst
Cyster i æggestokkene eller forstørrelse af æggestokkene
Ovarian cysts or enlargement of the ovaries
Cyster på æggestokkene (med symptomer som underlivssmerter og blødning).
ovarian macrocysts (with symptoms such as pelvic pain, bleeding)
Cyster på æggestokkene, brystsmerter og bækkensmerter.
Sacs of fluid within the ovaries (ovarian cysts), breast pain and pelvic pain.
cyster, ansigtssmerter, lokaliseret ødem
cyst, facial pain, localised oedema
Cystinindhold i leukocytter (mindste kvadraters gennemsnit ± standardfejl) i nmol hemicystin/mg protein
WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein
Cystinosis er en metabolisk sygdom, der hedder ”nephropatisk cystinosis”, som karakteriseres ved en unormal ophobning af aminosyren cystein i visse organer f.eks. nyrer, øjne, bugspytkirtlen og hjernen.
Cystinosis is a metabolic disease called ‘nephropathic cystinosis’ which is characterized by an abnormal accumulation of the amino acid cystine in various organs of the body such as the kidney, eye, muscle, pancreas, and brain.
Cystisk fibrose er en arvelig sygdom, der hovedsagelig angriber lungernes slimproducerende celler og de kirtelceller i tarmen og bugspytkirtlen, der udskiller fordøjelsesvæsker.
Cystic fibrosis is an inherited disease that mainly affects the cells that secrete mucus in the lungs, and the cells that secrete digestive juices from the glands in the gut and pancreas.
Cystisk fibrose forårsaget af en mutation i F508del er imidlertid særlig alvorlig, hvorfor CHMP fandt, at de iagttagne virkninger var klinisk relevante for patienter uden andre behandlingsmuligheder.
However, as cystic fibrosis caused by F508del mutation is particularly severe the CHMP considered that the observed effects seen were clinically relevant for patients with no other alternative options.
Cystisk fibrose skyldes mutationer i CFTR-genet.
Cystic fibrosis is caused by mutations of the CFTR gene.
Cystocele, endometrielidelse, endometriehypertrofi* (ultralydsbestemt endometrietykkelse), uteruspolyp, vaginalt udflåd, vaginal sygdom
Cystocele, endometrial disorder, endometrial hypertrophy* (sonographic endometrial thickness), uterine polyp, vaginal discharge, vaginal disorder
Cystoidt maculaødem betragtes som en sværere undertype af makulært ødem, og i øjeblikket anføres der kun "makulært ødem" i produktresumeet.
Cystoid Macular Oedema is considered to be a more severe subtype of macular oedema and currently only ‘macular oedema’ listed in the SmPC.
Cystoidt makulaødem (nethinden i øjet svulmer op, så man får dårligere syn)
Cystoid macular oedema (swelling of the retina within the eye leading to worsening vision)
cystoidt makulaødem, hævelse af øjet, sløret syn
cystoid macular oedema, eye swelling, vision blurred
cystoidt makulaødem, sløret syn
cystoid macular oedema, vision blurred
Cystometriske undersøgelser af patienter med en overaktiv blære, der er karaktereriseret ved detrusorinstabilitet eller hyperrefleksia, har vist, at oxybutynin forøger den maksimale urinblærekapacitet og forøger volumen til første kontraktion af detrusor.
In patients with overactive bladder, characterised by detrusor muscle instability or hyperreflexia, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.
Cytarabin omdannes intracellulært til den aktive metabolit, cytarabin-5- triphosphat (ara-CTP).
Intracellularly, cytarabine is converted into cytarabine-5’-triphosphate (ara-CTP), which is the active metabolite.
Cytarabins primære eliminationsvej er omdannelse til den inaktive forbindelse ara-U (1--D- arabinofuranosyluracil eller uracilarabinosid), fulgt af udskillelse af ara-U via urinen.
The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, (1--D- arabinofuranosyluracil or uracil arabinoside) followed by urinary excretion of ara-U.
Cytochrom P450-CYP1A2 og P450-CYP2D6 bidrager til dannelsen af N-desmethyl og 2-hydroxymethyl metabolitterne, der udviser signifikant mindre in vivo farmakologisk aktivitet end olanzapin i dyrestudier.
Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Cytochrom P450-CYP1A2 og P450-CYP2D6 bidrager til dannelsen af N-desmethyl og 2-hydroxymethyl metabolitterne, der udviser signifikant mindre in vivo farmakologisk aktivitet end olanzapin i dyrestudier.
P450-CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2- hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Cytochrom P450-CYP1A2 og P450-CYP2D6 bidrager til dannelsen af N-desmethyl og 2-hydroxymethyl metabolitterne, der udviser signifikant mindre in vivo farmakologisk aktivitet end olanzapin i dyreundersøgelser.
Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Cytochrom P450-CYP1A2 og P450-CYP2D6 bidrager til dannelsen af N-desmethyl og 2-hydroxymethyl metabolitterne, der udviser signifikant mindre in vivo farmakologisk aktivitet end olanzapin i dyreundersøgelser.
Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites; both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Cytochrom P450-enzymer samt konjugationsreaktioner er ikke involveret i metabolismen af efalizumab.
Cytochrome P450 enzymes as well as conjugation reactions are not involved in the metabolism of efalizumab.
Cytochroom P450 2C19 (CYP2C19)
Cytochrome P450 2C19 (CYP2C19)
Cytogene analyser hos 1. linje-B-CLL-patienter:
Cytogenetic Analyses in first line B-CLL patients:
Cytogenetik efter TRISENOX terapi
Cytogenetics after TRISENOX therapy
Cytogenetisk bekræftelse af konversion til en normal genotype og påvisning ved revers transkriptase – polymerasekædereaktion (RT-PCR) af PML/RAR konversion til normal er vist i tabellen nedenfor.
Cytogenetic confirmation of conversion to a normal genotype and Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) detection of PML/RAR conversion to normal are shown in the table below.
Cytogenetisk hovedrespons2
Major cytogenetic response2
Cytogenetisk hovedrespons2 Fuldstændigt (Bekræftet3) [95% CI] Delvist
Majorcytogenetic response2
Cytogenetisk kategori
Cytogenetic category
Cytogenetisk respons
Cytogenetic response
Cytogenetisk respons var baseret på procentdelen af Ph+ metafaser blandt ≥ 20 metafaseceller i hver knoglemarvsprøve.
Cytogenetic responses were based on the percentage of Ph+ metaphases among >/= 20 metaphase cells in each bone marrow sample.
Cytogenetiske abnormiteter blev evalueret hos 117 af hele populationen på
Cytogenetic abnormalities were evaluated in 117 of the total population of 176 patients.
Cytogenetiske abnormiteter blev evalueret hos 117 af hele populationen på
Cytogenetic abnormalities were evaluated in 117 of the total population of 176patients.